Skip to main content

Table 1 Baseline characteristics of the different ATN classifications according to different cut-off values

From: Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease

ATN class

Number of patients (% of total)

Age range (median; Q1–Q3)

Sex male/female (% male)

Median MMSE at baseline

A. Based on thresholds of 798 pg/mL for Aβ42, 87 pg/mL for p181-tau, and 465 pg/mL for t-tau

 A−/T−/N−

73

(32.02%)

47–83

(67; 59–72)

41/32

(56.16%)

26

 A+/T−/N−

76

(33.33%)

49–85

(66.5; 60–72)

39/37

(51.32%)

25.5

 A+/T+/N+

39

(17.11%)

51–83

(69; 65–74.5)

20/19

(51.28%)

23

 A+/T−/N+

27

(11.84%)

50–80

(68; 64–73)

11/16

(40.74%)

22

 A−/T−/N+

10

(4.39%)

56–83

(64.5; 59.75–66)

7/3

(70%)

26

 A−/T+/N+

3

(1.32%)

66–74

(71; 68.5–72.5)

1/2

(33.33%)

22

 A−/T+/N−

0

(0%)

NA

NA

NA

 A+/T+/N−

0

(0%)

NA

NA

NA

 Total

228

47–85

(66; 60–72.25)

119/109

(52.19%)

25

B. Based on thresholds of 798 pg/mL for Aβ42, 58.9 pg/mL for p181-tau, and 354 pg/mL for t-tau

 A−/T−/N−

63

(27.63%)

47–83

(65; 58–72)

39/24

(61.90%)

25

 A+/T−/N−

57

(25.00%)

49–85

(65; 60–72)

30/27

(52.63%)

26

 A+/T+/N+

63

(27.63%)

51–83

(69; 64.5–74)

28/35

(44.44%)

26

 A+/T−/N+

20

(8.77%)

50–79

(68.5; 60–72.5)

11/9

(55.00%)

23

 A−/T−/N+

5

(2.19%)

66–76

(72; 67–72)

0/5

(0%)

27

 A−/T+/N+

14

(6.14%)

56–83

(65.5; 62.5–67.75)

9/5

(64.29%)

26

 A−/T+/N−

4

(1.75%)

61–74

(69.5; 65.5–72.5)

1/3

(25.00%)

26

 A+/T+/N−

2

(0.88%)

75–78

(76.5;75.75–77.25)

1/1

(50.00%)

26

 Total

228

47–85

(66; 60–72.25)

119/109

(52.19%)

25

  1. ATN amyloid/tau/neurodegeneration, MMSE Mini Mental State Examination, NA not applicable